Jason M. Broderick

Atezolizumab with chemotherapy did not yield a significant increase to event-free survival compared with placebo with chemotherapy, 85.2% vs 81.9%, respectively.

Six-year data from the OlympiA trial support olaparib as a standard of care in BRCA-mutated, high-risk, HER2-negative primary breast cancer.

Long-term ORR, DOR, PFS, and OS data from the phase 2 Zuma-5 trial supports the use of axi-cel use in relapsed/refractory indolent Non-Hodgkin lymphoma treatment.

Tisagenlecleucel shows high rates of MRD-negative status among patients with relapsed/refractory follicular lymphoma in the ELARA trial.

All evaluable patients achieved minimal residual disease negativity following teclistamab-based treatment in the phase 3 MajesTEC-4/EMN30 trial.

Data from the EMBARK trial show no significant differences in sexual activity and urinary symptoms when suspending treatment with enzalutamide.

CHAARTED2 trial showed an improved progression-free survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, abiraterone acetate, and prednisone.

If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non–muscle invasive bladder cancer, says Sandip Prasad, MD.

Data from the phase 3 CS-003 study underscore the importance of long-term follow-up findings with novel therapies for high-grade non–muscle-invasive bladder cancer, says Stephen A. Boorjian MD.

More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.

Efficacy and safety data from the phase 2b SUNRISE-1 trial support the ongoing evaluations of TAR-200 as a treatment for patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.

Data from the phase 3 EV-302 trial support enfortumab vedotin plus pembrolizumab as a potential standard of care in locally advanced or metastatic urothelial carcinoma.

Lenvatinib plus pembrolizumab generates no new safety signals among patients with advanced renal cell carcinoma in the phase 3 CLEAR study.

The combination is also associated with a manageable toxicity profile in the second and subsequent treatment lines for patients with advanced renal cell carcinoma.

The findings indicate that nephron sparing management should be prioritized in elderly patients with kidney cancer when it is safe and feasible, according to the study authors.

At a median follow-up of 17.4 months, half of the enrolled patients with metastatic castration-resistant prostate cancer experienced a decrease in PSA level from baseline following treatment with tazemetostat in combination with abiraterone acetate or enzalutamide.

The findings, according to the lead study author from UC San Diego School of Medicine, are a proof of concept and need to be confirmed in a phase 2 trial.

Theranostics may fill an unmet need for a group of patients with high-risk localized prostate cancer, but more research is needed to identify how oncology providers can integrate it with the standard treatments, according to an expert from the University of Texas MD Anderson Cancer Center.

Patients with prostate cancer who experienced an increase in prostate-specific antigen level after radical prostatectomy appeared to benefit from a short course of androgen deprivation therapy after post-operative immediate salvage radiotherapy.

Data from the phase 3 SPOTLIGHT trial indicated that 18F-rhPSMA-7.3 PET yielded a positive detection rate in patients with recurrent prostate cancer, and increased along with prostate-specific antigen level.

Findings from the phase 2 KEYNOTE-B61 trial demonstrated promising efficacy with a combination of pembrolizumab and lenvatinib in the frontline treatment of non–clear cell renal cell carcinoma.

Findings from the phase 3 PRESTO trial indicated that patients with high-risk biochemically recurrent prostate cancer may derive benefit from treatment with androgen deprivation therapy intensification and apalutamide.

Data from the phase 3 IMmotion010 trial revealed no benefit of adjuvant atezolizumab vs placebo for resectable renal cell carcinoma.

A post-hoc analysis of the phase 3 TITAN trial revealed potential biomarkers that may predict overall survival in patients with metastatic castration-resistant prostate cancer receiving apalutamide plus androgen deprivation therapy.

Data presented at 2022 ASCO reveals PET-imaging characteristics linked with 177Lu-PSMA-617 efficacy in metastatic castration-resistant prostate cancer.

A manageable safety profile and good clinical activity were observed with toripalimab in Chinese patients with urothelial carcinoma.

Results of the COSMIC-021 trial presented at ASCO 2022 show promise of cabozantinib plus atezolizumab for urothelial carcinoma.

Interim results from the phase 2 PADRES trial demonstrated that partial nephrectomy may be possible for a subgroup of patients with clear cell renal cell carcinoma with complex masses who received neoadjuvant axitinib.

Data from the NeoAvAx trial presented at 2022 ASCO GU show potential for neoadjuvant avelumab plus axitinib for high-risk, non-metastatic clear-cell renal cell carcinoma.